ALOX12: Polyunsaturated fatty acid lipoxygenase ALOX12
Catalyzes the regio and stereo-specific incorporation of molecular oxygen into free and esterified polyunsaturated fatty acids generating lipid hydroperoxides that can be further reduced to the corresponding hydroxy species.
- Drugs that act on it: 1
- Approved: 1
- In phases 1 to 3: 0
- Sponsors: 0
Who is on it, and how far along
Every drug ChEMBL records acting on ALOX12, by the furthest stage it has reached for any use, coloured by modality.
How to read this
Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
- Small molecule 1
| Drug | Furthest stage | Sponsor | Modality | Action | Open trials |
|---|---|---|---|---|---|
| BenoxaprofenWithdrawn | Approved | — | Small molecule | InhibitorArachidonate 12-lipoxygenase inhibitor | 0 |
- Inflammation0.37
- Rheumatic disorder0.37
- Venous thromboembolism0.34
- Neurodegenerative disease0.34
- Colorectal cancer0.19
- Esophageal cancer0.19
- Coronary atherosclerosis0.11
- Esophageal squamous cell carcinoma0.10
- Cholelithiasis0.10
- Cancer0.10
- Neoplasm0.09
- Gastric cancer0.09
Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3687, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-21. Gene name, function (UniProt P18054, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets